BioCentury
ARTICLE | Company News

Evolva Holding, U.S. Department of Defense infectious news

September 1, 2014 7:00 AM UTC

Evolva received a $6.5 million contract from the DoD’s Defense Threat Reduction Agency (DTRA) to fund the first 15-month stage of preclinical development for GC-072, a broad-spectrum antibiotic. GC-07...